Diabetes

  • Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
    Richard Sekerak, MD, Johanna Ben-Ami Lerner, MD, Pooja Prasad, MD and Megha Prasad, MD
    Cleveland Clinic Journal of Medicine October 2023, 90 (10) 607-609; DOI: https://doi.org/10.3949/ccjm.90a.23004

    These conditions often co-exist and can have complex interactions. The progression of kidney disease increases the risk of major adverse cardiovascular events.

  • Inpatient glycemic management in noncritically ill patients: Updated guidelines
    Michelle D. Lundholm, MD and Oscar L. Morey-Vargas, MD
    Cleveland Clinic Journal of Medicine October 2023, 90 (10) 615-618; DOI: https://doi.org/10.3949/ccjm.90a.23049

    The guidelines include a role for newer diabetes technologies and nontraditional insulin and noninsulin therapies.

  • Born again: The many lives of metformin
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine September 2023, 90 (9) 523-524; DOI: https://doi.org/10.3949/ccjm.90b.09023

    Repurposing old drugs for new indications is not a new drug-development strategy.

  • Should I consider metformin therapy for weight loss in patients with obesity but without diabetes?
    Paloma Rodriguez, MD, Kevin M. Pantalone, DO, ECNU, FACE, Marcio L. Griebeler, MD and Bartolome Burguera, MD, PhD
    Cleveland Clinic Journal of Medicine September 2023, 90 (9) 545-548; DOI: https://doi.org/10.3949/ccjm.90a.22096

    The authors appraise the evidence to date for weight loss with metformin in this patient population.

  • The role of GLP-1 receptor agonists in managing type 2 diabetes
    Cleveland Clinic Journal of Medicine October 2022, 89 (10) 597;

    The following article in the August 2022 issue contained an error: Nachawi N, Rao PP, Makin V. The role of GLP-1 receptor agonists in managing type 2 diabetes. Cleve Clin J Med 2022; 89(8): 457–464. doi:10.3949/ccjm.89a.21110

  • The role of GLP-1 receptor agonists in managing type 2 diabetes
    The role of GLP-1 receptor agonists in managing type 2 diabetes
    Noura Nachawi, MD, Pratibha PR Rao, MD, MPH and Vinni Makin, MBBS, MD, FACE
    Cleveland Clinic Journal of Medicine August 2022, 89 (8) 457-464; DOI: https://doi.org/10.3949/ccjm.89a.21110

    A review of the evidence regarding the benefits and adverse effects of GLP-1 receptor agonists in patients with type 2 diabetes mellitus or obesity.

  • Glycemic targets in the ICU: A look back, and ahead
    Keren Zhou, MD
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 189-190; DOI: https://doi.org/10.3949/ccjm.89a.21127

    Much work is still needed to understand the nuances of glycemic targets in critically ill patients, and to learn how to take advantage of evolving technology to improve glycemic control.

  • Glycemic control in the critically ill: Less is more
    Ghaith Alhatemi, MD, Haider Aldiwani, MD, Rafal Alhatemi, MD, Marwah Hussein, MD, Suzan Mahdai, MD and Berhane Seyoum, MD
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 191-199; DOI: https://doi.org/10.3949/ccjm.89a.20171

    The authors discuss findings from key trials, metrics of glycemic control, and recommendations of professional societies for target blood glucose ranges in critically ill patients.

  • Hypercalcemia and vitamin A: A vitamin to keep in mind
    Saif Munther Borgan, MD, Leila Zeinab Khan, MD and Vinni Makin, MD, FACE
    Cleveland Clinic Journal of Medicine February 2022, 89 (2) 99-105; DOI: https://doi.org/10.3949/ccjm.89a.21056

    Vitamin A toxicity can affect bone resorption and hypercalcemia and should be explored in unexplained cases of parathyroid hormone-independent hypercalcemia.

  • A large, painless bulla on the right foot
    Jorge Camilo Mora, MD, MPH and Amalia Galindez, MD, FACP
    Cleveland Clinic Journal of Medicine January 2022, 89 (1) 10-12; DOI: https://doi.org/10.3949/ccjm.89a.21051

    A patient with a history of type 2 diabetes and diabetic neuropathy had a hemoglobin A1c of 10.3% at presentation.

Pages